Login to Your Account

Other News To Note

Wednesday, October 2, 2013
• Biotie Therapies Corp., of Turku, Finland, said that its partner H. Lundbeck A/S, of Copenhagen, has brought Selincro (nalmefene) to the market in Italy, triggering a €2 million (US$1.9 million) milestone to Biotie.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription